about
Who says this is a modern disorder? The early history of attention deficit hyperactivity disorderProfile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorderEstimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015Professionals' perceptions about healthcare resources for co-occuring disorders in SpainAdd-on gabapentin in the treatment of opiate withdrawal.Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile.Nonmedical use of prescription drugs in the European UnionBipolar disorder associated to substance use disorders (dual diagnosis). Systematic review of the scientific evidence and expert consensus.Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies.Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition.Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions.Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders.Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis.Unplanned versus planned discharges from in-patient alcohol detoxification: retrospective analysis of 470 first-episode admissions.The significance of a coexisting opioid use disorder in cocaine dependence: an empirical study.[Pharmacological treatment of substance dependence from a neuroscientific perspective (I): opiates and cocaine][Pharmacological treatment of substance dependence from a neuroscientific perspective (II): alcohol, benzodiazepines and nicotine]Does anyone care about names? How attendees at substance misuse services like to be addressed by health professionals.Dual diagnosis resource needs in Spain: a national survey of professionals.Anorgasmia in a patient treated with bupropion SR for smoking cessation.State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain.[Attention and craving. Advances in its conceptualization and its implications for relapse prevention].[Study on drug use among students in the province of Valencia, Spain].[Post-traumatic stress disorder and substance use disorder: treatment intervention].One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving.What makes alcohol-dependent individuals early in abstinence crave for alcohol: exposure to the drink, images of drinking, or remembrance of drinks past?Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis.Gender differences in cocaine dependent patients: a 6 month follow-up study.Homosexual delusional jealousy in two heterosexual women.Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit.Emergence of a Pan-European College of Addictions.Validation of the Spanish version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).Chronic Hepatitis C and people with a history of injecting drugs in Spain: population assessment, challenges for effective treatment.Clinical guideline for the treatment of dual pathology in the adult populationRethinking Dual Disorders/PathologyIndicadores de calidad asistencial de GESIDA para la atención de personas infectadas por el virus de la inmunodeficiencia adquirida/sida y metadona[Post-traumatic stress disorder and substance use disorder: epidemiology, nature and neurobiology]
P50
Q26770331-53BD6538-2657-4CDA-8047-7E09A4E672EEQ27692647-0A25982D-D9ED-43D2-A642-95367C33079AQ28391248-342DC557-F08D-4B3E-AFC6-4CC863019992Q34151138-81653AB5-514A-40F2-9475-46CAEA12ED7DQ34314545-4F7D9F64-7AA5-4155-BECB-662123EA215BQ35126898-49B56A3D-E7ED-46D5-B6B2-1058F99275A0Q36094236-9412630C-CF89-40E0-A472-5CBFBB3E1731Q37273537-2E0CF0D9-B96B-45BA-B545-8400B23C9368Q37561278-974479CA-19FD-4424-B23D-A5925F69B2DEQ37722786-6C2943DF-161E-40AC-8DA9-7A8ADB1810CBQ38060572-B4083AFF-6FFA-4853-AA1C-F316EF89A1DAQ38120961-7AE9E552-69F5-49B0-BD7F-194AC36D8C19Q38269902-30335AA9-AA70-4C6B-BDF2-070BAF8BE01AQ39147824-416D1999-3630-4F62-9F7D-F392164A30DAQ40893375-177028C9-376D-4685-AB8A-8B1A9560018FQ43239166-10A4482F-2094-4977-AAEF-79ED24B7EA9DQ43988691-6467C8D3-B8F1-4C30-B2AF-3981085625D9Q44342150-D67B4FDB-198B-4EF3-8655-9DD7F2A4E6F9Q44499827-AF63E315-40CF-4CA5-B649-E91E59F5F870Q44616830-3891F961-F91B-4FD5-8458-321E7089FAD7Q44788923-B1077AB3-3B99-4EAA-B2F1-CB1F844C1387Q44830974-58099D31-2048-43FD-90CA-177B35618612Q44962425-6580DBB7-4C4F-4FF9-BAFF-63EE9B21A484Q45046169-3DB45031-AD17-464F-84AF-DE32356A1EA0Q46179947-2F1CC6F4-2DA2-4B34-B0AC-4F1FEE8C8B82Q46278403-3869D1F3-3482-4001-8DA3-4CD92AB22117Q46825417-6D3B425B-F577-4C90-B607-EC621F51127AQ48421994-EF9666D6-C015-4C7E-9591-FD617E1C531CQ48713346-62C5D42C-7951-4E9E-8528-AAA5F5F35185Q49198771-5F478EFC-7F89-46D5-BB90-24442F215104Q50974059-CC7C1702-D392-4219-9C81-26ABADBE0E4DQ51027423-29115031-CAA6-48D3-81F4-F42B48F87AE4Q52280868-856E1B12-B0BE-4F7F-9ECC-424268C094BAQ52282472-7A01EEE5-43F4-4F43-9082-7A3ADC0C0013Q52304532-770B87DD-43E4-4258-B6A7-6BBB6E0DEB4DQ52312926-23F97AAF-38EC-4398-B0E9-75E60C2466A5Q53586934-6A6F2EE1-9122-4434-86F8-AB1CD0F921D5Q58439985-9C29845C-34C6-4D06-87AD-A9F22CA61551Q58440023-41AE42B0-2B06-4132-8EBB-3766CFD17333Q58440088-CCAF874D-AFB8-4346-BDBD-AB6F2536C8E2
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jose Martinez-Raga
@ast
Jose Martinez-Raga
@en
Jose Martinez-Raga
@es
Jose Martinez-Raga
@nl
Jose Martinez-Raga
@sl
type
label
Jose Martinez-Raga
@ast
Jose Martinez-Raga
@en
Jose Martinez-Raga
@es
Jose Martinez-Raga
@nl
Jose Martinez-Raga
@sl
altLabel
J Martinez Raga
@en
JM Raga
@en
prefLabel
Jose Martinez-Raga
@ast
Jose Martinez-Raga
@en
Jose Martinez-Raga
@es
Jose Martinez-Raga
@nl
Jose Martinez-Raga
@sl
P1053
B-6251-2017
P106
P1153
6603786648
P21
P31
P3829
P496
0000-0002-2856-6562